Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FLGC NASDAQ:KTTA NASDAQ:MDCX NASDAQ:QCLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGCFlora Growth$4.77+2.8%$5.78$5.86▼$47.00$4.99M1.939,454 shs4,775 shsKTTAPasithea Therapeutics$0.65-9.8%$0.74$0.28▼$2.06$17.83M0.25352,177 shs1.48 million shsMDCXMedicus Pharma$0.33-4.0%$0.36$0.25▼$3.69$19.73M0.142.81 million shs1.60 million shsQCLSMymd Pharmaceuticals$4.10-2.4%$0.00$2.50▼$33.56$17.50M2.17675,508 shs439,916 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGCFlora Growth+2.80%+11.58%-8.11%-26.84%-80.89%KTTAPasithea Therapeutics-9.79%-5.16%-23.31%-21.34%-30.65%MDCXMedicus Pharma-4.02%+14.49%+17.17%-75.78%-87.29%QCLSMymd Pharmaceuticals-2.38%+4.06%+409,999,900.00%+409,999,900.00%+409,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGCFlora Growth$4.77+2.8%$5.78$5.86▼$47.00$4.99M1.939,454 shs4,775 shsKTTAPasithea Therapeutics$0.65-9.8%$0.74$0.28▼$2.06$17.83M0.25352,177 shs1.48 million shsMDCXMedicus Pharma$0.33-4.0%$0.36$0.25▼$3.69$19.73M0.142.81 million shs1.60 million shsQCLSMymd Pharmaceuticals$4.10-2.4%$0.00$2.50▼$33.56$17.50M2.17675,508 shs439,916 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGCFlora Growth+2.80%+11.58%-8.11%-26.84%-80.89%KTTAPasithea Therapeutics-9.79%-5.16%-23.31%-21.34%-30.65%MDCXMedicus Pharma-4.02%+14.49%+17.17%-75.78%-87.29%QCLSMymd Pharmaceuticals-2.38%+4.06%+409,999,900.00%+409,999,900.00%+409,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLGCFlora Growth 2.00Hold$30.00528.93% UpsideKTTAPasithea Therapeutics 1.67Reduce$3.00365.12% UpsideMDCXMedicus Pharma 2.25Hold$9.002,592.19% UpsideQCLSMymd Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest FLGC, KTTA, QCLS, and MDCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026QCLSMymd Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (E+)4/21/2026MDCXMedicus Pharma Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/20/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/20/2026MDCXMedicus Pharma D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.004/10/2026MDCXMedicus Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/2/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026KTTAPasithea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/19/2026MDCXMedicus Pharma D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.003/9/2026MDCXMedicus Pharma D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLGCFlora Growth$57.61M0.09N/AN/A$12.21 per share0.39KTTAPasithea TherapeuticsN/AN/AN/AN/A$2.39 per shareN/AMDCXMedicus PharmaN/AN/AN/AN/AN/AN/AQCLSMymd PharmaceuticalsN/AN/AN/AN/A$5.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLGCFlora Growth-$15.91M-$32.49N/AN/AN/A-32.03%-64.02%-34.46%N/AKTTAPasithea Therapeutics-$20.43M-$2.08N/AN/AN/AN/A-57.44%-53.61%6/3/2026 (Estimated)MDCXMedicus Pharma-$35.46M-$2.68N/AN/AN/AN/A-3,137.84%-311.33%8/10/2026 (Estimated)QCLSMymd Pharmaceuticals-$11.63M-$20.69N/AN/AN/AN/A-76.40%-35.10%N/ALatest FLGC, KTTA, QCLS, and MDCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/AKTTAPasithea Therapeutics-$3.40N/AN/AN/A$0.30 millionN/A5/15/2026Q1 2026KTTAPasithea Therapeutics-$0.45-$0.12+$0.33-$0.12$0.10 millionN/A5/15/2026Q1 2026QCLSMymd PharmaceuticalsN/A-$0.19N/A-$0.19N/AN/A5/14/2026Q1 2026MDCXMedicus Pharma-$0.18-$0.31-$0.13-$0.31N/AN/A4/15/2026Q4 2025QCLSMymd PharmaceuticalsN/A$6.11N/A$6.11N/AN/A3/30/2026Q4 2025KTTAPasithea Therapeutics-$0.18-$0.89-$0.71-$0.89$0.10 millionN/A3/26/2026Q4 2025MDCXMedicus Pharma-$0.32-$0.82-$0.50-$0.83N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFLGCFlora GrowthN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/AQCLSMymd PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLGCFlora GrowthN/A2.081.79KTTAPasithea TherapeuticsN/A35.4135.41MDCXMedicus PharmaN/A1.221.22QCLSMymd PharmaceuticalsN/A3.723.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLGCFlora Growth36.01%KTTAPasithea Therapeutics23.92%MDCXMedicus PharmaN/AQCLSMymd Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipFLGCFlora Growth2.34%KTTAPasithea Therapeutics2.00%MDCXMedicus Pharma8.10%QCLSMymd Pharmaceuticals0.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFLGCFlora Growth2801.05 million1.02 millionNot OptionableKTTAPasithea Therapeutics324.94 million24.44 millionNot OptionableMDCXMedicus PharmaN/A56.66 million52.07 millionN/AQCLSMymd Pharmaceuticals64.17 million4.13 millionN/AFLGC, KTTA, QCLS, and MDCX HeadlinesRecent News About These CompaniesMymd Pharmaceuticals (NASDAQ:QCLS) Upgraded by Wall Street Zen to Hold RatingMay 23, 2026 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLGC, KTTA, QCLS, and MDCX Company DescriptionsFlora Growth NASDAQ:FLGC$4.77 +0.13 (+2.80%) As of 06/1/2026Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.Pasithea Therapeutics NASDAQ:KTTA$0.64 -0.07 (-9.79%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$0.66 +0.02 (+2.95%) As of 06/2/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Medicus Pharma NASDAQ:MDCX$0.33 -0.01 (-4.02%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$0.33 0.00 (-0.99%) As of 06/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.Mymd Pharmaceuticals NASDAQ:QCLS$4.10 -0.10 (-2.38%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$4.10 0.00 (-0.12%) As of 06/2/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? FirstCash Turns Pawn Into a Growth Machine HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
